M&A / Deals Daiichi exits OTC, with $1.55bn unit sale to Suntory PharmaphorumDaiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.M&A / DealsRead full story pharminent April 15, 2026 Pharmaphorum Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debutNext: Parkinson’s charity partners Biognosys on biomarker project Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
